Menstrual Toxic Shock Syndrome: A Comprehensive Exploration of Pathophysiology, Risk Factors, and Management Strategies
Main Article Content
Abstract
Menstrual Toxic Shock Syndrome (mTSS) stands as a rare yet potentially life-threatening condition, characterized by a cascade of systemic effects resulting from the release of toxic shock syndrome toxin-1 (TSST-1) and other superantigens during menstruation. This article aims to provide an in-depth analysis of the pathophysiological mechanisms underlying mTSS, elucidate the diverse array of risk factors contributing to its development, and present contemporary strategies for the management and prevention of this enigmatic syndrome. By synthesizing current research findings and clinical insights, this comprehensive review seeks to enhance our understanding of mTSS, fostering improved diagnostic precision and optimizing patient outcomes.
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
References
I. Toxic-shock syndrome (other than streptococcal) (TSS): 2011 case definition. Atlanta: Centers for Disease Control and Prevention; reviewed 2021 Apr. 16.
Available:https://ndc.services.cdc.gov/case-definitions/toxic-shock-syndrome-2011/ (accessed 2022 Jan. 7).
II. Berger S, Kunerl A, Wasmuth S, et al. Menstrual toxic shock syndrome: case report and systematic review of the literature. Lancet Infect Dis 2019;19:e313–21.CrossRefGoogle Scholar
III. Schlievert PM, Davis CC. Device-associated menstrual toxic shock syndrome. Clin Microbiol Rev 2020;33:e00032–19.
IV. Coopersmith CM, De Backer D, Deutschman CS, Ferrer R, Lat I, Machado FR, Martin GS, Martin-Loeches I, Nunnally ME, Antonelli M, Evans LE, Hellman J, Jog S, Kesecioglu J, Levy MM, Rhodes A. Surviving Sepsis Campaign: Research Priorities for Sepsis and Septic Shock. Crit Care Med. 2018 Aug;46(8):1334-1356.
V. Schmitz M, Roux X, Huttner B, Pugin J. Streptococcal toxic shock syndrome in the intensive care unit. Ann Intensive Care. 2018 Sep 17;8(1):88.
VI. Lamagni TL, Darenberg J, Luca-Harari B, Siljander T, Efstratiou A, Henriques-Normark B, Vuopio-Varkila J, Bouvet A, Creti R, Ekelund K, Koliou M, Reinert RR, Stathi A, Strakova L, Ungureanu V, Schalén C, Strep-EURO Study Group. Jasir A. Epidemiology of severe Streptococcus pyogenes disease in Europe. J Clin Microbiol. 2008 Jul;46(7):2359-67.
VII. Lappin E, Ferguson AJ. Gram-positive toxic shock syndromes. Lancet Infect Dis. 2009 May;9(5):281-90.
VIII. Guirgis F, Black LP, DeVos EL. Updates and controversies in the early management of sepsis and septic shock. Emerg Med Pract. 2018 Oct;20(10):1-28.
IX. Barrier KM. Summary of the 2016 International Surviving Sepsis Campaign: A Clinician's Guide. Crit Care Nurs Clin North Am. 2018 Sep;30(3):311-321.
X. Descloux E, Perpoint T, Ferry T, Lina G, Bes M, Vandenesch F, Mohammedi I, Etienne J. One in five mortality in non-menstrual toxic shock syndrome versus no mortality in menstrual cases in a balanced French series of 55 cases. Eur J Clin Microbiol Infect Dis. 2008 Jan;27(1):37-43
XI. Robinson KA, Rothrock G, Phan Q, Sayler B, Stefonek K, Van Beneden C, Levine OS., Active Bacterial Core Surveillance/Emerging Infections Program Network. Risk for severe group A streptococcal disease among patients' household contacts. Emerg Infect Dis. 2003 Apr;9(4):443-7.